A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults
View ORCID ProfileJenny G. Low, Ruklanthi de Alwis, Shiwei Chen, View ORCID ProfileShirin Kalimuddin, Yan Shan Leong, Tania Ken Lin Mah, Natalene Yuen, Hwee Cheng Tan, Summer L Zhang, Jean X.Y. Sim, Yvonne F.Z. Chan, View ORCID ProfileAyesa Syenina, Jia Xin Yee, View ORCID ProfileEugenia Z. Ong, View ORCID ProfileRose Sekulovich, Brian B. Sullivan, Kelly Lindert, Sean B. Sullivan, Pad Chivukula, View ORCID ProfileSteven G. Hughes, View ORCID ProfileEng Eong. Ooi
doi: https://doi.org/10.1101/2021.07.01.21259831
